Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy
Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy
Germ cell tumors, a relatively rare disease, but most common malignancy in young males, occur
 most frequently in testis. The incidence is about 1%, but is increasing in the majority of
 developed countries. The testicular cancer is an extremely important oncological condition
 due to his high rate of 80-90% of curability, which can be achieved by combination of
 chemotherapy and surgery.

 Some of 20-30% of patients will experience disease progression after first line
 cisplatin-based chemotherapy and salvage 2nd line conventional-dose cisplatin-based salvage
 chemotherapy will result in long term remissions in < 50% of patients (VeIP - vinblastine,
 ifosfamide, cisplatin, VIP/PEI - ifosfamide, etoposide, cisplatin, TIP - paclitaxel,
 ifosfamide, cisplatin). In multiple relapsed patients the 3rd line chemotherapy can induce
 remission in up to 40% (gemcitabine, oxaliplatin), 23% RR (TG - paclitaxel, gemcitabine), 20%
 CR (IPO - irinotecan, paclitaxel, oxaliplatin), but only small proportion of them can be
 cured, usually with subsequent consolidation surgery. At that stage the disease is usually
 chemorefractory and there are no other chemotherapy regimens of proven benefit (7).

 The purpose of this study is to determine if multiple-relapsed chemorefractory pts may
 benefit from sorafenib monotherapy.
Inclusion Criteria:

 1. Male patients > 18 years of age

 2. Patients with histologically proven germ cell neoplasm (gonadal or extragonadal
 primary)

 3. Patients must have the disease not amendable to cure with either surgery or
 chemotherapy

 4. Patients must have failed at least two cisplatin-based combination chemotherapy
 regimens.

 5. Failure on prior regimens will be defined as either:

 -  A ≥ 25% increase in sum of target lesions, new lesions, or

 -  An increasing AFP or HCG above the nadir level.

 6. Patients with at least one measurable lesion by CT scan or MRI according to RECIST
 criteria

 7. Adequate bone marrow, liver and renal function, assessed no longer than 14 days before
 treatment start, defined by the following laboratory test limits: WBC > 2.0 x 109/l
 and platelets > 60 x 109/l, total bilirubin < 2 x upper limit, AST and ALT < 5 x upper
 limit normal, serum creatinine < 2 x UNL

 8. WHO Performance Status 0, 1, 2

 9. No concurrent chemotherapy or radiotherapy

 10. Life expectancy of at least 12 weeks

 11. Absence of any physiological, familial, sociological or geographical condition
 potentially hampering compliance with the study protocol and follow-up schedule

 12. A signed informed consent must be obtained prior to any study specific procedures

 13. All patients must agree to use adequate contraception during the whole study period

 Exclusion Criteria:

 1. Patients not fulfilling of inclusion criteria

 2. Primary radiotherapy in the field of target lesion

 3. Major surgery (RPLND) within 4 weeks before the start of study drug or concurrent
 serious non-healing wounds, ulcers or bone fractures.

 4. Known serious and active bacterial, viral or fungal infection (> grade II CTC-AE)
 including HBV, HCV and HIV carrier state.

 5. Previous or concurrent malignancy except for basal cell carcinoma of the skin

 6. Uncontrolled hypertension.

 7. Thrombotic or embolic event in last 6 months prior to inclusion.

 8. Impairment of gastrointestinal tract, or GI disease that may influence the
 bioavailability of oral sorafenib

 9. Substance and alcohol abuse (nicotine use is allowed)

 10. Known or suspected hypersensitivity to sorafenib.

 11. Participants in any other clinical trial using investigational drug within 4 weeks
 prior to study entry

 12. Prior use of investigational or licensed angiogenesis and RAF kinase or MEK
 inhibitors.

 13. Patient unwilling or unable to give informed consent

 14. Any condition that may in the investigator's opinion jeopardize the safety of the
 patient or his compliance in the study.